Artal Group S.A. Incyte Corp Call Options Transaction History

Artal Group S.A.

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2020 May 14, 2020	SELL	$63.18 - $85.97 $6.32 Million - $8.6 Million	-100,000 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$73.04 - $95.72 $11 Million - $14.4 Million	-150,000 Reduced 60.0%	100,000 $8.73 Million
Q2 2019 Aug 09, 2019	BUY	$73.52 - $88.7 $18.4 Million - $22.2 Million	250,000 New	250,000 $21.2 Million
Q2 2018 Aug 10, 2018	SELL	$60.85 - $83.98 $33.5 Million - $46.2 Million	-550,000 Closed	0 $0
Q1 2018 May 10, 2018	BUY	$83.06 - $100.98 $24.9 Million - $30.3 Million	300,000 Added 120.0%	550,000 $45.8 Million
Q4 2017 Feb 09, 2018	BUY	$93.56 - $116.6 $9.36 Million - $11.7 Million	100,000 Added 66.67%	250,000 $23.7 Million
Q3 2017 Nov 08, 2017	BUY	$109.15 - $138.27 $16.4 Million - $20.7 Million	150,000	150,000 $17.5 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.7B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.